3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 4
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
40
NIH
8
NETWORK
8
INDUSTRY
4
OTHER_GOV
2
UNKNOWN
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Urinary Bladder Neoplasms
1
Pancreatic Neoplasms
1
Interventions
Capecitabine
28
apatinib
26
Oxaliplatin
24
Cisplatin
24
tislelizumab
23
Gemcitabine
23
Irinotecan
19
Paclitaxel
18
Carboplatin
18
Docetaxel
15
Bevacizumab
15
Fluorouracil
14
Drug Therapy
13
Cyclophosphamide
11
pembrolizumab
10
camrelizumab
10
Vinorelbine
9
Radiation
9
S 1 (combination)
8
Leucovorin
8
Cetuximab
8
toripalimab
7
sintilimab
7
Rituximab
7
Erlotinib Hydrochloride
7
pyrotinib
6
Gefitinib
6
Albumin-Bound Paclitaxel
6
fludarabine
5
anlotinib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
OTHER_GOV
×
Mitomycin
×
Clear all
NCT06388720
2026-05-29
IMGeS
National Cancer Center, Korea
Phase 2
Recruiting
82 enrolled
NCT06233877
2024-02-28
GFLIPM
Hirschfeld Oncology
Phase 2
Not yet recruiting
60 enrolled